Maze Therapeutics, Inc. cash flow statement MAZE

In fiscal 2025, which ended Dec 31, 2025, Maze Therapeutics, Inc. used $111.9 million of cash from operations. It spent $794,000 on capital expenditures. Free cash flow was negative, at -$112.7 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
Operating
Depreciation and amortization
2
2
Stock-based compensation
26
16
Operating cash flow
-107
-112
Investing
Capital expenditures
0
1
Investing cash flow
-293
-171
Financing
Financing cash flow
337
275
Change in cash
Free cash flow
-107
-113
Per share
Free cash flow per share
-2.02
-2.62
Ratios
Free cash flow margin
-56.98%
-67.30%
Capital expenditures to revenue
0.16%
0.47%
Stock-based compensation to revenue
13.99%
9.79%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
MAZE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
South San Francisco, CA
SEC filer status
, Emerging growth company
SEC CIK
1842295

Other Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.